Navigation Links
Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
Date:2/10/2009

nted Mr. Armstrong. "MSI-1436 continues to exhibit promise as the only PTP1B inhibitor in development to simultaneously treat both type 2 diabetes and obesity. Our recent identification of a novel binding site we believe is the key to its selectivity and safety to date. We are anxious to begin our first study of subcutaneously administered MSI-1436 to human subjects, which is planned for later this year."

In Cohort 1 of Study 102, five subjects received MSI-1436 while two subjects received placebo, with results suggesting that MSI-1436 is well-tolerated, with no serious adverse events, no severe adverse events and no dose-limiting toxicities reported. In addition to the favorable adverse event profile seen in the cohort, the multiple-dose PK of MSI-1436 was found to be similar to the PK profiles following single intravenous dosing in two previous phase 1 studies.

About Trodusquemine (MSI-1436)

Trodusquemine is the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme central to controlling the function of both the leptin and insulin pathways. By inhibiting both central and peripheral PTP1B, MSI-1436 is expected to decrease appetite and normalize blood sugar. Initial clinical studies of trodusquemine in obese and overweight subjects has provided early indicators of weight loss and improved glucose control. These results confirm previous work in animal models which demonstrated significant weight loss without metabolic rebound, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune,
'/>"/>

SOURCE Genaera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
2. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
3. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
5. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
6. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
7. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
8. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
9. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
10. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
11. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... is available in its catalogue: Germany ... 2020 http://www.reportlinker.com/p02343442/Germany-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html ... Outlook to 2020 Summary GlobalData,s new ... Outlook to 2020", provides key market data on ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- EDGE Orthopaedics, a new entry in ... announce they have received their second FDA 510(k) ... Fracture Plating System. The VIEW Plating ... indications within the mid-foot. The system includes titanium ... (CC), Talonavicular (TN) and Evans plates along with ...
(Date:8/28/2014)... CITY , Aug. 28, 2014 /PRNewswire-iReach/ -- Academy ... by service academy graduates, has published a case ... three-day Leadership Excellence Course . In September and ... Excellence Course to Albuquerque , Indianapolis ... . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
Breaking Medicine Technology:Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 9EDGE Orthopaedics Receives Second FDA Clearance 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... Cancer Journal , AUSTIN, Texas--(BUSINESS WIRE)--May 30, 2007--Introgen,Therapeutics, ... the dramatic clinical benefit of its lead product,Advexin ... of cancer known as,Li-Fraumeni Syndrome (LFS), a genetic ... suppressor gene. This is the,first reported treatment of ...
... CITY, Calif.--(BUSINESS WIRE)--May 29, 2007 - Gilead,Sciences, ... III,AIR-CF1 (CP-AI-007) study of aztreonam lysine for ... fibrosis (CF) who have,pulmonary Pseudomonas aeruginosa (P. ... at Day 28 from baseline in respiratory,symptoms, ...
Cached Medicine Technology:Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 2Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 3Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 2Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 3Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 5
(Date:8/29/2014)... neuroregenerative effect, stimulating neurite extension in the ... and enhancing nerve regeneration following nerve crush ... FK506 to stimulate nerve regeneration is limited ... and hypertension, and its considerable cost. With ... other drugs reportedly cause life-threatening infections. Like ...
(Date:8/29/2014)... August 29, 2014 The Fresh Diet, ... introduce its new Fresh Vegetarian meal plan. Originating from ... meals, the new menu is designed to satisfy customers ... lifestyle. , Responding to the growing demand ... a multi-billion dollar market (Forbes) with 14% of Americans ...
(Date:8/29/2014)... 2014 Glendale Botox experts at ... Botox throughout the month of September. This special offer features ... syringes of Juvederm. Patients can take advantage of this special ... Glendale Botox experts will work with patients to determine if ... What is Botox? , Botox is a treatment made ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Researchers have ... in their brains. Dyslexia -- the most commonly ... problems with reading and writing. Previous research showed ... but most of those studies focused only on a ... used functional MRI to analyze how multiple brain regions ...
(Date:8/29/2014)... VA (PRWEB) August 29, 2014 For ... Research Foundation (Meso Foundation) will be observing September 26th ... on Rockefeller Plaza, in New York. , Members ... encouraged to RSVP . The Foundation will be providing ... the past years, mesothelioma community members have received attention ...
Breaking Medicine News(10 mins):Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 3Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Scientists Find Differences in Brains of Those With Dyslexia 2Health News:Organization to Raise Awareness of Mesothelioma on the Today Show 2
... of Psychiatry at Case Western Reserve University School of Medicine ... Institute of Mental Health (NIMH) for the long-term study of ... NIMH, one of the National Institutes of Health (NIH), funds ... which 707 children between the ages of six and 12 ...
... By Maryann Mott HealthDay Reporter , THURSDAY, ... twice before snuggling in bed at night with Fido or ... issue of the public health journal Emerging Infectious Diseases ... that cause mild to life-threatening illness in people. Of ...
... HealthDay Reporter , THURSDAY, Jan. 20 (HealthDay ... greatly increases the chances of dying, new research ... analysis, of previously published studies that looked at ... Six of seven studies found pre-existing diabetes was ...
... (HealthDay News) -- Many young American couples can,t agree on ... a new study shows. Oregon State University researchers analyzed ... 18 to 25. In 40 percent of those couples, one ... the other partner said there was no such deal. ...
... paper published Jan. 21 in the journal Science , ... Blossom Damania, PhD, has shown for the first time that ... a key molecule involved in the human immune response. ... Kenan, Jr. Distinguished Professor, Jenny Ting, PhD. First ...
... Ky. Healthcare workers can most directly affect quality of ... helping manage symptoms such as pain, lack of energy, shortness ... a study recently published in the journal Oncology Nursing ... or the degree to which a symptom bothers a person, ...
Cached Medicine News:Health News:Case Western Reserve receives $7.8M to study manic symptoms in children 2Health News:Case Western Reserve receives $7.8M to study manic symptoms in children 3Health News:Pets May Pass Illnesses to Owners 2Health News:Pets May Pass Illnesses to Owners 3Health News:Breast Cancer Patients With Diabetes May Fare Worse 2Health News:Breast Cancer Patients With Diabetes May Fare Worse 3Health News:Young Couples Often Disagree About Monogamy, Study Finds 2Health News:Viral protein mimic keeps immune system quiet 2Health News:Controlling symptoms can lead to improved quality of life for end-of-life patients 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: